Clinical Trials Directory

Trials / Terminated

TerminatedNCT00609154

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Albert Einstein College of Medicine · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.

Detailed description

We will measure the rate of new insulin production in subjects with Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2 diabetes make less insulin in response to GLP-1 compared to non diabetic subjects.

Conditions

Interventions

TypeNameDescription
DRUGglucagon like peptide-1GLP-1 1 pmole/kg/min
DIETARY_SUPPLEMENTglucose controlglucose without GLP-1

Timeline

Start date
2010-08-12
Primary completion
2014-05-13
Completion
2014-05-13
First posted
2008-02-06
Last updated
2024-02-28
Results posted
2024-02-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00609154. Inclusion in this directory is not an endorsement.